119 related articles for article (PubMed ID: 11365875)
1. Twice daily Indinavir trial stopped.
TreatmentUpdate; 1998 Oct; 10(8):3-4. PubMed ID: 11365875
[TBL] [Abstract][Full Text] [Related]
2. Twice-daily dosing Crixivan study discontinued.
WORLD; 1998 Oct; (No 90):7. PubMed ID: 11365922
[TBL] [Abstract][Full Text] [Related]
3. Crixivan warning: keep to three times a day.
Gilden D
GMHC Treat Issues; 1998 Sep; 12(9):2. PubMed ID: 11365805
[TBL] [Abstract][Full Text] [Related]
4. Merck discontinues twice-daily dosing of Crixivan.
Res Initiat Treat Action; 1998 Oct; 4(6):13. PubMed ID: 11365914
[TBL] [Abstract][Full Text] [Related]
5. Twice-a-day Crixivan study discontinued.
Newsline People AIDS Coalit N Y; 1998; ():31. PubMed ID: 11367502
[TBL] [Abstract][Full Text] [Related]
6. Crixivan (Indinavir): three doses daily, not two, in most regimens.
James JS
AIDS Treat News; 1998 Oct; (No 304):4-5. PubMed ID: 11365863
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
[TBL] [Abstract][Full Text] [Related]
8. No more twice-a-day Crixivan.
Vazquez E
Posit Aware; 1998; 9(6):17. PubMed ID: 11366469
[TBL] [Abstract][Full Text] [Related]
9. Twice-daily Indinavir dosing not recommended.
Highleyman L
BETA; 1998 Oct; ():4. PubMed ID: 11365990
[TBL] [Abstract][Full Text] [Related]
10. Spring cleaning in trial land.
Gilden D
GMHC Treat Issues; 1997 Mar; 11(3):4-7. PubMed ID: 11364275
[TBL] [Abstract][Full Text] [Related]
11. Indinavir, nelfinavir -- twice a day?
TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365434
[TBL] [Abstract][Full Text] [Related]
12. Different combinations of ritonavir-indinavir.
TreatmentUpdate; 2001 Sep; 13(5):1-2. PubMed ID: 11768859
[No Abstract] [Full Text] [Related]
13. Crixivan reduces viral load.
AIDS Patient Care STDS; 1996 Feb; 10(1):50. PubMed ID: 11361665
[No Abstract] [Full Text] [Related]
14. Another option for less than 50 T4 cells.
Treat Rev; 1995; (no 19):3. PubMed ID: 11362755
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
16. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
[TBL] [Abstract][Full Text] [Related]
17. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
[TBL] [Abstract][Full Text] [Related]
18. Eradication of HIV: the cutting edge of clinical trial design.
Crit Path AIDS Proj; 1996; (No 31):16-7. PubMed ID: 11363825
[TBL] [Abstract][Full Text] [Related]
19. [More transparency facilities drug choice in general practice. Booster regimens in direct comparison].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():82. PubMed ID: 12043090
[No Abstract] [Full Text] [Related]
20. Indinavir (Crixivan).
Treat Rev; 1996 Apr; (no 21):7. PubMed ID: 11363398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
